Pulmonary function tests (PFTs) are invaluable tools in the diagnosis, monitoring, and management of respiratory diseases. The interpretation of these tests, however, can be complex and challenging, necessitating a comprehensive understanding for accurate clinical application.
PFTs primarily assess three parameters: lung volumes, airflow, and gas exchange. Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1), and their ratio (FEV1/FVC) are the key indicators of airflow. Total Lung Capacity (TLC), Residual Volume (RV), and Functional Residual Capacity (FRC) depict lung volumes. Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) measures gas exchange.
Spirometry is the cornerstone of PFTs. Normal FEV1/FVC ratio is above 0.7. A decreased ratio suggests obstructive disease, while normal or increased ratio with decreased volumes indicates restrictive pattern. The severity of obstruction or restriction is classified based on FEV1 or FVC percentages of predicted values.
Increased RV and FRC suggest air trapping, common in obstructive diseases. Decreased TLC indicates restrictive disease. A reduced DLCO points towards impaired gas exchange, seen in interstitial lung disease and pulmonary vascular disorders. However, it might be normal in pure airway diseases like asthma.
Interpretation of PFTs should always be integrated with clinical context and other investigations. For instance, a normal DLCO in a patient with reduced volumes and FEV1/FVC ratio may favor a diagnosis of asthma over COPD. Conversely, a reduced DLCO in a patient with normal spirometry could suggest early interstitial lung disease.
Interpreting PFTs is a vital skill for healthcare professionals involved in respiratory care. A thorough understanding of the basic parameters, coupled with an ability to integrate these results with clinical context, can greatly enhance diagnostic accuracy and patient management.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation